{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T18:23:06Z","timestamp":1775326986107,"version":"3.50.1"},"reference-count":50,"publisher":"The Ewha Medical Journal, Ewha Womans University College of Medicine","issue":"s1","license":[{"start":{"date-parts":[[2023,12,31]],"date-time":"2023-12-31T00:00:00Z","timestamp":1703980800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["www.e-emj.org"],"crossmark-restriction":true},"short-container-title":["Ewha Med J"],"DOI":"10.12771\/emj.2023.e31","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T05:47:44Z","timestamp":1705297664000},"update-policy":"https:\/\/doi.org\/10.12771\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Updates in the Management of Graves Disease in Children"],"prefix":"10.12771","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2847-2643","authenticated-orcid":false,"given":"Yun Jeong","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4998","published-online":{"date-parts":[[2023,12,31]]},"reference":[{"issue":"10","key":"key2.024011506525e+13_B1","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamapediatrics.2016.0486","article-title":"Thyroid disorders in children and adolescents: a review","volume":"170","author":"Hanley","year":"2016","journal-title":"JAMA Pediatr"},{"issue":"12","key":"key2.024011506525e+13_B2","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaoto.2021.2715","article-title":"Management of pediatric graves disease: a review","volume":"147","author":"Quintanilla-Dieck","year":"2021","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"3","key":"key2.024011506525e+13_B3","doi-asserted-by":"crossref","first-page":"192","DOI":"10.6065\/apem.2142168.084","article-title":"Predictors of associated and multiple autoimmunity in children and adolescents with type 1 diabetes mellitus","volume":"27","author":"Kakleas","year":"2022","journal-title":"Ann Pediatr Endocrinol Metab"},{"issue":"8","key":"key2.024011506525e+13_B4","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1210\/jc.2018-00273","article-title":"Epidemiology of childhood hyperthyroidism in France: a nationwide population-based study","volume":"103","author":"Simon","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"key2.024011506525e+13_B5","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000430985","article-title":"Increasing incidence of juvenile thyrotoxicosis in Denmark: a nationwide study, 1998-2012","volume":"84","author":"Havgaard Kjaer","year":"2015","journal-title":"Horm Res Paediatr"},{"issue":"7","key":"key2.024011506525e+13_B6","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1089\/thy.2010.1636","article-title":"Environmental exposures and autoimmune thyroid disease","volume":"20","author":"Brent","year":"2010","journal-title":"Thyroid"},{"issue":"4","key":"key2.024011506525e+13_B7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.6065\/apem.2244186.093","article-title":"Impact of iodine intake on the pathogenesis of autoimmune thyroid disease in children and adults","volume":"27","author":"Kalarani","year":"2022","journal-title":"Ann Pediatr Endocrinol Metab"},{"issue":"10","key":"key2.024011506525e+13_B8","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"issue":"1","key":"key2.024011506525e+13_B9","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-21-0073","article-title":"2022 European thyroid association guideline for the management of pediatric Graves' disease","volume":"11","author":"Mooij","year":"2022","journal-title":"Eur Thyroid J"},{"issue":"4","key":"key2.024011506525e+13_B10","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/archdischild-2022-323905","article-title":"Graves' disease: moving forwards","volume":"108","author":"Lane","year":"2023","journal-title":"Arch Dis Child"},{"key":"key2.024011506525e+13_B11","doi-asserted-by":"crossref","first-page":"2619695","DOI":"10.1155\/2017\/2619695","article-title":"Efficacy of once daily versus divided daily administration of low daily dosage (15 mg\/day) of methimazole in the induction of euthyroidism in Graves' hyperthyroidism: a randomized controlled study","volume":"2017","author":"Sriussadaporn","year":"2017","journal-title":"Int J Endocrinol"},{"issue":"12","key":"key2.024011506525e+13_B12","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1210\/clinem\/dgac573","article-title":"Approach to the patient: management and the long-term consequences of Graves' disease in children","volume":"107","author":"Rivkees","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"key2.024011506525e+13_B13","doi-asserted-by":"crossref","first-page":"199","DOI":"10.6065\/apem.2142046.023","article-title":"Efficacy and adverse events related to the initial dose of methimazole in children and adolescents with Graves' disease","volume":"26","author":"Lee","year":"2021","journal-title":"Ann Pediatr Endocrinol Metab"},{"issue":"2","key":"key2.024011506525e+13_B14","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1089\/thy.2012.0612","article-title":"Antithyroid drug treatment for Graves' disease in children: a long-term retrospective study at a single institution","volume":"24","author":"Ohye","year":"2014","journal-title":"Thyroid"},{"issue":"2","key":"key2.024011506525e+13_B15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1530\/EJE-21-0077","article-title":"Methimazole-induced remission rates in pediatric Graves' disease: a systematic review","volume":"185","author":"van Lieshout","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"key2.024011506525e+13_B16","doi-asserted-by":"crossref","first-page":"R59","DOI":"10.1530\/EJE-16-0938","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: arguments for the prolonged use of antithyroid drugs in children with Graves' disease","volume":"177","author":"L\u00e9ger","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"key2.024011506525e+13_B17","doi-asserted-by":"crossref","first-page":"308","DOI":"10.6065\/apem.2244038.019","article-title":"Remission in pediatric Graves' disease treated with antithyroid drug and the risk factors associated with relapse","volume":"27","author":"Wong","year":"2022","journal-title":"Ann Pediatr Endocrinol Metab"},{"issue":"5","key":"key2.024011506525e+13_B18","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-3034","article-title":"Long-term methimazole therapy in juvenile Graves' disease: a randomized trial","volume":"143","author":"Azizi","year":"2019","journal-title":"Pediatrics"},{"issue":"10","key":"key2.024011506525e+13_B19","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1089\/thy.2019.0814","article-title":"Long-term treatment of hyperthyroidism with antithyroid drugs: 35 years of personal clinical experience","volume":"30","author":"Azizi","year":"2020","journal-title":"Thyroid"},{"issue":"1","key":"key2.024011506525e+13_B20","article-title":"Antithyroid drug regimen for treating Graves' hyperthyroidism","volume":"2010","author":"Abraham","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"key2.024011506525e+13_B21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/cen.14046","article-title":"How do paediatricians use and monitor antithyroid drugs in the UK? A clinician survey","volume":"91","author":"Lawrence","year":"2019","journal-title":"Clin Endocrinol"},{"issue":"6","key":"key2.024011506525e+13_B22","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1530\/EJE-20-0617","article-title":"Randomised trial of block and replace vs dose titration thionamide in young people with thyrotoxicosis","volume":"183","author":"Wood","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"key2.024011506525e+13_B23","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40618-019-01144-0","article-title":"\"Block-and-replace\" treatment in Graves' disease: experience in a cohort of pediatric patients","volume":"43","author":"Vigone","year":"2020","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"key2.024011506525e+13_B24","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-21-0043","article-title":"Initial response of young people with thyrotoxicosis to block and replace or dose titration thionamide","volume":"11","author":"Wood","year":"2022","journal-title":"Eur Thyroid J"},{"issue":"2","key":"key2.024011506525e+13_B25","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s12020-023-03371-1","article-title":"Long-term outcome of treatments for Graves disease in the children and adolescent population","volume":"81","author":"Jawwad","year":"2023","journal-title":"Endocrine"},{"issue":"9","key":"key2.024011506525e+13_B26","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3345\/kjp.2009.52.9.1021","article-title":"Remission rate and remission predictors of Graves disease in children and adolescents","volume":"52","author":"Lee","year":"2009","journal-title":"Korean J Pediatr"},{"issue":"4","key":"key2.024011506525e+13_B27","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3345\/kjp.2010.53.4.585","article-title":"The natural history and prognostic factors of Graves' disease in Korean children and adolescents","volume":"53","author":"Song","year":"2010","journal-title":"Korean J Pediatr"},{"issue":"1","key":"key2.024011506525e+13_B28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.6065\/apem.2012.17.1.33","article-title":"The clinical course and prognostic factors to medical treatment of Graves' disease in children and adolescents","volume":"17","author":"Kim","year":"2012","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"key2.024011506525e+13_B29","doi-asserted-by":"crossref","first-page":"687834","DOI":"10.3389\/fendo.2021.687834","article-title":"Long-term antithyroid drug treatment of Graves' disease in children and adolescents: a 20-year single-center experience","volume":"12","author":"Song","year":"2021","journal-title":"Front Endocrinol"},{"issue":"4","key":"key2.024011506525e+13_B30","doi-asserted-by":"crossref","first-page":"266","DOI":"10.6065\/apem.2040286.143","article-title":"Long-term outcomes of Graves' disease in children and adolescents receiving antithyroid drugs","volume":"26","author":"Rho","year":"2021","journal-title":"Ann Pediatr Endocrinol Metab"},{"issue":"4","key":"key2.024011506525e+13_B31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.6065\/apem.2120143edi01","article-title":"Commentary on \"long-term outcomes of Graves' disease in children and adolescents receiving antithyroid drugs\"","volume":"26","author":"Kim","year":"2021","journal-title":"Ann Pediatr Endocrinol Metab"},{"issue":"4","key":"key2.024011506525e+13_B32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.6065\/apem.2222019edi04","article-title":"Commentary on \"remission in pediatric Graves' disease treated with antithyroid drug and the risk factors associated with relapse\"","volume":"27","author":"Kim","year":"2022","journal-title":"Ann Pediatr Endocrinol Metab"},{"issue":"5","key":"key2.024011506525e+13_B33","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jpeds.2013.12.047","article-title":"Graves disease in children: thyroid-stimulating hormone receptor antibodies as remission markers","volume":"164","author":"Gastaldi","year":"2014","journal-title":"J Pediatr"},{"issue":"1","key":"key2.024011506525e+13_B34","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1210\/jc.2011-1944","article-title":"French Childhood Graves' Disease Study Group. Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves' disease: national long-term cohort study","volume":"97","author":"L\u00e9ger","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"key2.024011506525e+13_B35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00247-022-05415-6","article-title":"Radioiodine treatment of pediatric Graves disease: a multicenter review","volume":"53","author":"Trout","year":"2023","journal-title":"Pediatr Radiol"},{"issue":"5","key":"key2.024011506525e+13_B36","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000517174","article-title":"The efficacy and short- and long-term side effects of radioactive iodine treatment in pediatric Graves' disease: a systematic review","volume":"10","author":"Lutterman","year":"2021","journal-title":"Eur Thyroid J"},{"issue":"9","key":"key2.024011506525e+13_B37","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1210\/jc.2003-031223","article-title":"A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patients","volume":"89","author":"Read","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"key2.024011506525e+13_B38","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/j.jpedsurg.2019.02.009","article-title":"Surgical management of pediatric thyroid disease: complication rates after thyroidectomy at the Children's hospital of Philadelphia high-volume pediatric thyroid center","volume":"54","author":"Baumgarten","year":"2019","journal-title":"J Pediatr Surg"},{"issue":"1","key":"key2.024011506525e+13_B39","doi-asserted-by":"crossref","first-page":"26","DOI":"10.6065\/apem.2244044.022","article-title":"Risk factors of postoperative hypoparathyroidism after total thyroidectomy in pediatric patients with thyroid cancer","volume":"28","author":"Choe","year":"2023","journal-title":"Ann Pediatr Endocrinol Metab"},{"issue":"12","key":"key2.024011506525e+13_B40","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1093\/bjs\/znad255","article-title":"Thyroid surgery in children and adolescents: results from a multi-institutional German and Austrian database","volume":"110","author":"Weber","year":"2023","journal-title":"Br J Surg"},{"issue":"1","key":"key2.024011506525e+13_B41","first-page":"39","article-title":"Thyroidectomy in pediatric patients with Graves' disease: a systematic review of postoperative morbidity","volume":"10","author":"Zaat","year":"2020","journal-title":"Eur Thyroid J"},{"issue":"11","key":"key2.024011506525e+13_B42","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1089\/thy.2019.0085","article-title":"The long-term outcome of treatment for Graves' hyperthyroidism","volume":"29","author":"Sj\u00f6lin","year":"2019","journal-title":"Thyroid"},{"issue":"1","key":"key2.024011506525e+13_B43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/cen.14374","article-title":"Comparison of long-term antithyroid drugs versus radioactive iodine or surgery for Graves' disease: a review of the literature","volume":"95","author":"El Kawkgi","year":"2021","journal-title":"Clin Endocrinol"},{"issue":"6","key":"key2.024011506525e+13_B44","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1210\/endrev\/bnaa022","article-title":"New therapeutic horizons for Graves' hyperthyroidism","volume":"41","author":"Lane","year":"2020","journal-title":"Endocr Rev"},{"issue":"16","key":"key2.024011506525e+13_B45","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves' disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"key2.024011506525e+13_B46","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1210\/clinem\/dgab763","article-title":"Adjuvant rituximab: exploratory trial in young people with Graves disease","volume":"107","author":"Cheetham","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"key2.024011506525e+13_B47","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1210\/clinem\/dgz013","article-title":"A novel anti-CD40 monoclonal antibody, iscalimab, for control of Graves hyperthyroidism: a proof-of-concept trial","volume":"105","author":"Kahaly","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"(Suppl 1)","key":"key2.024011506525e+13_B48","doi-asserted-by":"crossref","first-page":"A778","DOI":"10.1210\/jendso\/bvac150.1609","article-title":"ODP509 proof-of-concept, multicenter, open-label phase 2a study of batoclimab in active and moderate-to-severe thyroid eye disease","volume":"6","author":"Janes","year":"2022","journal-title":"J Endocr Soc"},{"issue":"6","key":"key2.024011506525e+13_B49","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/cen.14681","article-title":"TSH receptor specific monoclonal autoantibody K1-70\u2122 targeting of the TSH receptor in subjects with Graves' disease and Graves' orbitopathy: results from a phase I clinical trial","volume":"96","author":"Furmaniak","year":"2022","journal-title":"Clin Endocrinol"},{"issue":"7","key":"key2.024011506525e+13_B50","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1089\/thy.2019.0036","article-title":"Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves' hyperthyroidism: a phase I study","volume":"29","author":"Pearce","year":"2019","journal-title":"Thyroid"}],"container-title":["The Ewha Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.e-emj.org\/download\/download_pdf?doi=10.12771\/emj.2023.e31","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.e-emj.org\/download\/download_pdf?doi=10.12771\/emj.2023.e31","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T02:08:01Z","timestamp":1741226881000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-emj.org\/journal\/view.php?doi=10.12771\/emj.2023.e31"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,31]]},"references-count":50,"journal-issue":{"issue":"s1","published-online":{"date-parts":[[2023,12,31]]}},"alternative-id":["10.12771\/emj.2023.e31"],"URL":"https:\/\/doi.org\/10.12771\/emj.2023.e31","relation":{},"ISSN":["2234-2591"],"issn-type":[{"value":"2234-2591","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,31]]},"assertion":[{"value":"2023-10-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e31"}}